Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
Background: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. Methods: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977623005593 |
| _version_ | 1797430048066633728 |
|---|---|
| author | Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino |
| author_facet | Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino |
| author_sort | Massimo Di Maio |
| collection | DOAJ |
| description | Background: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. Methods: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter Italian GIM14/BIOMETA study were retrieved. Progression-free survival (PFS) over time was evaluated according to the type of anti-HER2 therapy, disease onset (de novo vs. relapsing), metastatic site, and year of treatment (2000–2013 vs. 2014–2020). Results: Median follow-up was 64.4 months. Overall, for first-line therapies, mPFS was 16.5 vs 19.5 months for patients treated in 2000–2013 vs 2014–2020 (HR: 0.78, 95% CI:0.65–0.94, P = 0.008). mPFS improved over time in all patients except for those with brain metastasis. Interestingly mPFS was 17.4 vs13.4 months (HR, 1.49; 95% CI, 1.13–1.98, P = 0.005) in 2000–2013 and 24.4 vs 20.9 months (HR 1.04; 95% CI 0.78–1.40 p = 0.77) in 2014–2020 in pts without vs with liver metastases. For second line therapies, the overall median PFS was 9.6 months (95% CI, 8.31–10.97) and did not change over time. Conclusion: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time. |
| first_indexed | 2024-03-09T09:22:02Z |
| format | Article |
| id | doaj.art-4d2b4ec77a90481d9884d1101fc4625e |
| institution | Directory Open Access Journal |
| issn | 1532-3080 |
| language | English |
| last_indexed | 2024-03-09T09:22:02Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj.art-4d2b4ec77a90481d9884d1101fc4625e2023-12-02T06:58:48ZengElsevierBreast1532-30802023-12-0172103583Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA studyMassimo Di Maio0Claudia Bighin1Francesco Schettini2Tommaso Ruelle3Laura Marandino4Alessandra Fabi5Carmine De Angelis6Mario Giuliano7Pietro De Placido8Michelino De Laurentiis9Ferdinando Riccardi10Caterina Picotto11Fabio Puglisi12Lucia Del Mastro13Grazia Arpino14Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, ItalyDepartment of Medical Oncology, U.O. Oncologia Medica 2, Ospedale Policlinico San Martino, Genoa, ItalyDepartment of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, ItalyDepartment of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, ItalyPrecision Medicine in Senology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, ItalyDepartment of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II, Naples, ItalyDepartment of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II, Naples, ItalyDepartment of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II, Naples, ItalyDepartment of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, ItalyOncology Unit, Antonio Cardarelli Hospital, Naples, ItalyDepartment of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, ItalyDepartment of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy; Department of Medicine (DAME), University of Udine, Udine, ItalyDepartment of Medical Oncology, U.O. Oncologia Medica 2, Ospedale Policlinico San Martino, Genoa, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, ItalyDepartment of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II, Naples, Italy; Corresponding author: , Oncology Division, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80100, Naples, Italy. +39 081 7463772Background: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. Methods: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter Italian GIM14/BIOMETA study were retrieved. Progression-free survival (PFS) over time was evaluated according to the type of anti-HER2 therapy, disease onset (de novo vs. relapsing), metastatic site, and year of treatment (2000–2013 vs. 2014–2020). Results: Median follow-up was 64.4 months. Overall, for first-line therapies, mPFS was 16.5 vs 19.5 months for patients treated in 2000–2013 vs 2014–2020 (HR: 0.78, 95% CI:0.65–0.94, P = 0.008). mPFS improved over time in all patients except for those with brain metastasis. Interestingly mPFS was 17.4 vs13.4 months (HR, 1.49; 95% CI, 1.13–1.98, P = 0.005) in 2000–2013 and 24.4 vs 20.9 months (HR 1.04; 95% CI 0.78–1.40 p = 0.77) in 2014–2020 in pts without vs with liver metastases. For second line therapies, the overall median PFS was 9.6 months (95% CI, 8.31–10.97) and did not change over time. Conclusion: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.http://www.sciencedirect.com/science/article/pii/S0960977623005593Breast cancerHER2-PositiveMetastasisFirst line of therapyTrastuzumab |
| spellingShingle | Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study Breast Breast cancer HER2-Positive Metastasis First line of therapy Trastuzumab |
| title | Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study |
| title_full | Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study |
| title_fullStr | Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study |
| title_full_unstemmed | Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study |
| title_short | Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study |
| title_sort | evolving treatments and outcomes in her2 positive metastatic breast cancer data from the gim14 biometa study |
| topic | Breast cancer HER2-Positive Metastasis First line of therapy Trastuzumab |
| url | http://www.sciencedirect.com/science/article/pii/S0960977623005593 |
| work_keys_str_mv | AT massimodimaio evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT claudiabighin evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT francescoschettini evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT tommasoruelle evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT lauramarandino evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT alessandrafabi evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT carminedeangelis evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT mariogiuliano evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT pietrodeplacido evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT michelinodelaurentiis evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT ferdinandoriccardi evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT caterinapicotto evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT fabiopuglisi evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT luciadelmastro evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy AT graziaarpino evolvingtreatmentsandoutcomesinher2positivemetastaticbreastcancerdatafromthegim14biometastudy |